Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market By Product Type (Prolastin C, Aralast NP, Glassia, and Zemaira/Reespreza), By End-User (Hospitals, Specialty Clinics, and Pharmacies), By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2023-2032
- Published date: Oct 2023
- Report ID: 95351
- Number of Pages: 370
- Format:
-
keyboard_arrow_up
-
-
- Grifols, S.A. (Spain)
- Kamada Pharmaceuticals
- CSL Limited
- Takeda Pharmaceutical Company Limited
- Teva Pharmaceutical Industries Ltd. Company Profile
- GlaxoSmithKline PLC
- Arrowhead Pharmaceutical, Inc.
- LFB Biomedicaments S.A.
- Mereo BioPharma Group plc
- Intellia Therapeutics, Inc.
- Inhibrx, Inc.
- Centessa Pharmaceuticals (Z factor)
- Krystal Biotech
- Beam Therapeutics
- LOGICBIO THERAPEUTICS, INC.
- Apic Bio
- Pfizer Inc Company Profile
- Other Key Players
Our Clients
- 95351
- Oct 2023
Trusted by more than 17382 organizations globally
✖
Request a Sample Report
We'll get back to you as quickly as possible
